CytomX Therapeutics, Inc.
CTMXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeCytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The $807.7M market capitalization puts CTMX squarely in small-cap range for its industry. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.
Market Cap
$807.7M
Beta
2.17
P/E (TTM)
—
P/E (Fwd)
-7.22
EPS (TTM)
$-0.52
EPS (Fwd)
$-0.51
ROE
-34.3%
ROA
-16.9%
Cash
$346.7M
Total Debt
$2.9M
Free CF
-$41.9M
52W Change
40.0%
Annual Financials
Cash vs Debt
CytomX Therapeutics, Inc. holds $346.7M in cash against $2.9M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$41.9M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -34.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $53.2M (2022) to $76.2M (2025), reflecting a 43% increase over the period.
CytomX Therapeutics, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, CTMX has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing CTMX.